Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Centex Studies Inc

Neither a doctor nor a teaching hospital

Research payments

$4,204,837

987 payments

Through program year 2025, Centex Studies Inc is reported as receiving $4,204,837 in research payments, across 987 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,212,857 256
2024 Research $70,472 4
2023 Research $3,620 2
2022 Research $87,280 7
2021 Research $58,685 66
2020 Research $220,487 99
2019 Research $2,551,436 553

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $1,283,329 260 payments
  2. AbbVie, Inc. $806,572 205 payments
  3. Intercept Pharmaceuticals, Inc. $523,780 81 payments
  4. Pfizer Inc. $486,166 34 payments
  5. Regeneron Pharmaceuticals, Inc. $257,601 8 payments
  6. Sanofi US Services Inc. $173,786 91 payments
  7. Eisai Inc. $166,879 110 payments
  8. Allergan Inc. $104,462 25 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $77,035 3 payments
  10. Novartis Pharmaceuticals Corporation $65,726 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $709,753 190 payments
  2. M16-100 $528,020 77 payments
  3. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $503,105 66 payments
  4. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $344,213 10 payments
  5. 1011866 $285,895 36 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee $257,601 8 payments
  7. 1009742 $237,885 45 payments
  8. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $166,879 110 payments
  9. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $138,713 17 payments
  10. M14-675 $74,165 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record